Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20379158 | 0.80 | CMA1 (0.39) | CMA1BRD9ALDH1A1KDM4ENPC1 | |
| SCHEMBL20379057 | 0.75 | CMA1 (0.48) | CMA1BRD9ALDH1A1KDM4ENPC1 | |
| SCHEMBL21373610 | 0.74 | QPCT (0.34) | — | |
| SCHEMBL20379065 | 0.74 | MAP3K11 (0.36) | ALDH1A1KDM4EMAOBALOX15HSD17B10 | |
| SCHEMBL20379413 | 0.73 | CMA1 (0.46) | CMA1BRD9ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL20379080 | 0.71 | CMA1 (0.43) | CMA1ALDH1A1KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL20379403 | 0.71 | CMA1 (0.43) | CMA1BRD9ALDH1A1KDM4ENPC1 | |
| SCHEMBL21384901 | 0.70 | CMA1 (0.42) | CMA1ALDH1A1KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL21381512 | 0.70 | MGLL (0.44) | CMA1ALDH1A1NPC1TP53RAB9A | |
| SCHEMBL20379397 | 0.70 | CMA1 (0.42) | CMA1ALDH1A1KDM4ENPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | claimed |
| US-11628159-B2 | Cell-protective compounds and their use | ETH ZURICH (CH) | 2023-04-18 | — | — | US | claimed |
| EP-3768673-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2021-01-27 | — | — | EP | claimed |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2021-01-21 | — | — | US | claimed |
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH Zürich (CH) | 2019-11-14 | — | — | US | claimed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | claimed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | claimed |
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | disclosed |
| CN-116462666-A | Cytoprotective compounds and uses thereof | 瑞士苏黎世联邦理工学院 | 2023-07-21 | — | — | CN | disclosed |
| US-11628159-B2 | Cell-protective compounds and their use | ETH ZURICH (CH) | 2023-04-18 | — | — | US | disclosed |
| EP-3768673-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2021-01-21 | — | — | US | disclosed |
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH Zürich (CH) | 2019-11-14 | — | — | US | disclosed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | SRPK2, SRSF2, SRPK1 | CYP19A1 4792/4885CMA1 3847/4885BRD9 3804/4885 |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | PPT1, SPTLC1, LPCAT1 | CYP19A1 3891/4885CMA1 1512/4885BRD9 2162/4885 |
| US-11628159-B2 | Cell-protective compounds and their use | SRPK2, SRSF2, SRPK1 | CYP19A1 4792/4885CMA1 3847/4885BRD9 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.